Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.54 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486605 | 0.90 | GPR119 (0.56) | GPR119 | |
| SCHEMBL709010 | 0.86 | GPR119 (0.55) | GPR119EGLN2IRAK4BACE1LMNA | |
| SCHEMBL532948 | 0.86 | GPR119 (0.55) | GPR119EGLN2IRAK4LMNAALDH1A1 | |
| SCHEMBL30062534 | 0.85 | GPR119 (0.54) | GPR119EGLN2IRAK4LMNAALDH1A1 | |
| SCHEMBL31153769 | 0.85 | KCNH2 (0.48) | GPR119EGLN2KCNH2BACE1LMNA | |
| SCHEMBL13156287 | 0.85 | GPR119 (0.54) | GPR119EGLN2IRAK4LMNAALDH1A1 | |
| SCHEMBL355131 | 0.85 | GPR119 (0.68) | GPR119EGLN2KCNH2 | |
| SCHEMBL29378266 | 0.85 | GPR119 (0.68) | GPR119EGLN2KCNH2 | |
| SCHEMBL631353 | 0.85 | GPR119 (0.54) | GPR119EGLN2IRAK4LMNAALDH1A1 | |
| SCHEMBL28711602 | 0.85 | GPR119 (0.52) | GPR119EGLN2KCNH2IRAK4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-19 | — | — | US | disclosed |
| WO-2009079593-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY1R, NPY5R | GPR119 58/4885EGLN2 144/4885KCNH2 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.